National Medical Products Administration · Full chronicle and history

On August 6, 2026, China's National Medical Products Administration officially approved a sustained-release capsule for the prevention of acute mountain sickness. Officials claimed it fills a gap in domestic medication, but because the regimen has been used internationally for decades, it has sparked public questions about delays in the approval process.

From May 10 to 15, 2026, the Shandong Provincial Drug Administration inspected Line 103 of the lyophilized powder injection workshop at Shandong Huatai Pharmaceutical, concluded that there was 1 serious defect and that the results were non-compliant, and decided to suspend production of amiodarone hydrochloride injection.